Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end.

Discussions with FDA and global regulatory agencies related to a single global Phase 3 study of zorevunersen continue to progress; Company to provide an update by year-end.

FDA has removed the Partial Clinical Hold on zorevunersen.

As of September 30, 2024, Company had $269.2 million in cash, cash equivalents, and marketable securities.